281 related articles for article (PubMed ID: 20926400)
1. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS
Clin Cancer Res; 2010 Nov; 16(22):5564-72. PubMed ID: 20926400
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
6. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
[TBL] [Abstract][Full Text] [Related]
9. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
10. Reovirus: Rationale and clinical trial update.
Lal R; Harris D; Postel-Vinay S; de Bono J
Curr Opin Mol Ther; 2009 Oct; 11(5):532-9. PubMed ID: 19806501
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Attard G; Kitzen J; Blagden SP; Fong PC; Pronk LC; Zhi J; Zugmaier G; Verweij J; de Bono JS; de Jonge M
Br J Cancer; 2007 Nov; 97(10):1338-43. PubMed ID: 18000498
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Lolkema MP; Arkenau HT; Harrington K; Roxburgh P; Morrison R; Roulstone V; Twigger K; Coffey M; Mettinger K; Gill G; Evans TR; de Bono JS
Clin Cancer Res; 2011 Feb; 17(3):581-8. PubMed ID: 21106728
[TBL] [Abstract][Full Text] [Related]
15. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Goel S; Desai K; Macapinlac M; Wadler S; Goldberg G; Fields A; Einstein M; Volterra F; Wong B; Martin R; Mani S
Invest New Drugs; 2006 Mar; 24(2):125-34. PubMed ID: 16683205
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Baz W; Nakhl F; El-Soueidi R; Forte F; Lowry J; Aoun N; Burton J
Anticancer Drugs; 2009 Jul; 20(6):508-12. PubMed ID: 19318913
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]